Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 239654, 9 pages
http://dx.doi.org/10.1155/2015/239654
Review Article

A Survey on the Computational Approaches to Identify Drug Targets in the Postgenomic Era

1Institute of Systems Biology, Shanghai University, Shanghai 200444, China
2Department of Mathematics, Shanghai University, Shanghai 200444, China
3Department of Computer Science, School of Electronics and Information Engineering, Tongji University, Shanghai 201804, China
4Key Laboratory of Systems Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China

Received 1 July 2014; Accepted 27 August 2014

Academic Editor: Hao-Teng Chang

Copyright © 2015 Yan-Fen Dai and Xing-Ming Zhao. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. DiMasi, R. W. Hansen, and H. G. Grabowski, “The price of innovation: new estimates of drug development costs,” Journal of Health Economics, vol. 22, no. 2, pp. 151–185, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. X. Wan, W. Zhang, L. Li, Y. Xie, W. Li, and N. Huang, “A new target for an old drug: Identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling,” Journal of Medicinal Chemistry, vol. 56, no. 6, pp. 2619–2629, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. W. J. Andrews, T. Panova, C. Normand, O. Gadal, I. G. Tikhonova, and K. I. Panov, “Old drug, new target: ellipticines selectively inhibit RNA polymerase I transcription,” Journal of Biological Chemistry, vol. 288, no. 7, pp. 4567–4582, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Kuhn, D. Szklarczyk, S. Pletscher-Frankild et al., “STITCH 4: integration of protein-chemical interactions with user data,” Nucleic Acids Research, vol. 42, no. 1, pp. D401–D407, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Knox, V. Law, T. Jewison et al., “DrugBank 3.0: a comprehensive resource for “Omics” research on drugs,” Nucleic Acids Research, vol. 39, no. 1, pp. D1035–D1041, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Iorio, R. Bosotti, E. Scacheri et al., “Discovery of drug mode of action and drug repositioning from transcriptional responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 33, pp. 14621–14626, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. M. J. Keiser, V. Setola, J. J. Irwin et al., “Predicting new molecular targets for known drugs,” Nature, vol. 462, no. 7270, pp. 175–181, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Tan, X. Ge, and L. Xie, “Structural systems pharmacology: a new frontier in discovering novel drug targets,” Current Drug Targets, vol. 14, no. 9, pp. 952–958, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Yamanishi, M. Araki, A. Gutteridge, W. Honda, and M. Kanehisa, “Prediction of drug-target interaction networks from the integration of chemical and genomic spaces,” Bioinformatics, vol. 24, no. 13, pp. i232–i240, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Yamanishi, M. Kotera, M. Kanehisa, and S. Goto, “Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework,” Bioinformatics, vol. 26, no. 12, Article ID btq176, pp. i246–i254, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Lamb, E. D. Crawford, D. Peck et al., “The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease,” Science, vol. 313, no. 5795, pp. 1929–1935, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Lamb, “The Connectivity Map: a new tool for biomedical research,” Nature Reviews Cancer, vol. 7, no. 1, pp. 54–60, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Iorio, R. Tagliaferri, and D. di Bernardo, “Identifying network of drug mode of action by gene expression profiling,” Journal of Computational Biology, vol. 16, no. 2, pp. 241–251, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Iskar, M. Campillos, M. Kuhn, L. J. Jensen, V. van Noort, and P. Bork, “Drug-induced regulation of target expression,” PLoS Computational Biology, vol. 6, no. 9, Article ID e1000925, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Subramanian, P. Tamayo, V. K. Mootha et al., “Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 43, pp. 15545–15550, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Iskar, G. Zeller, P. Blattmann et al., “Characterization of drug-induced transcriptional modules: towards drug repositioning and functional understanding,” Molecular systems biology, vol. 9, p. 662, 2013. View at Google Scholar · View at Scopus
  17. R. H. Shoemaker, “The NCI60 human tumour cell line anticancer drug screen,” Nature Reviews Cancer, vol. 6, no. 10, pp. 813–823, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. W. C. Reinhold, M. Sunshine, H. Liu et al., “CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set,” Cancer Research, vol. 72, no. 14, pp. 3499–3511, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Conda-Sheridan, P. V. N. Reddy, A. Morrell et al., “Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase i (Tdp1) and topoisomerase i (Top1),” Journal of Medicinal Chemistry, vol. 56, no. 1, pp. 182–200, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Yan, B. Shieh, P. Reigan et al., “Potent activity of indolequinones against human pancreatic cancer: identification of thioredoxin reductase as a potential target,” Molecular Pharmacology, vol. 76, no. 1, pp. 163–172, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Cheng, Q. Li, Y. Wang, and S. H. Bryant, “Identifying compound-target associations by combining bioactivity profile similarity search and public databases mining,” Journal of Chemical Information and Modeling, vol. 51, no. 9, pp. 2440–2448, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. N. M. Penrod and J. H. Moore, “Influence networks based on coexpression improve drug target discovery for the development of novel cancer therapeutics,” BMC Systems Biology, vol. 8, no. 1, article 12, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. S. P. Gygi, Y. Rochon, B. R. Franza, and R. Aebersold, “Correlation between protein and mRNA abundance in yeast,” Molecular and Cellular Biology, vol. 19, no. 3, pp. 1720–1730, 1999. View at Google Scholar · View at Scopus
  24. M. A. Yildirim, K.-I. Goh, M. E. Cusick, A.-L. Barabási, and M. Vidal, “Drug-target network,” Nature Biotechnology, vol. 25, no. 10, pp. 1119–1126, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Yao and A. Rzhetsky, “Quantitative systems-level determinants of human genes targeted by successful drugs,” Genome Research, vol. 18, no. 2, pp. 206–213, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Zhao and S. Li, “Network-based relating pharmacological and genomic spaces for drug target identification,” PLoS ONE, vol. 5, no. 7, Article ID e11764, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Zhang, L. Liu, S. Zhao, X. Wang, and S. Li, “Vitexicarpin acts as a novel angiogenesis inhibitor and its target network,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 278405, 13 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. X. Liang, H. Li, and S. Li, “A novel network pharmacology approach to analyse traditional herbal formulae: the Liu-Wei-Di-Huang pill as a case study,” Molecular BioSystems, vol. 10, no. 5, pp. 1014–1022, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Zhang, X. Wang, and S. Li, “An integrative platform of TCM network pharmacology and its application on a herbal formula, Qing-Luo-Yin,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 456747, 12 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. W.-C. Hwang, A. Zhang, and M. Ramanathan, “Identification of information flow-modulating drug targets: a novel bridging paradigm for drug discovery,” Clinical Pharmacology & Therapeutics, vol. 84, no. 5, pp. 563–572, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Zhu, L. Gao, X. Li et al., “The analysis of the drug-targets based on the topological properties in the human protein-protein interaction network,” Journal of Drug Targeting, vol. 17, no. 7, pp. 524–532, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Wang, Z.-P. Liu, X.-S. Zhang, and L. N. Chen, “Prediction of hot spots in protein interfaces using a random forest model with hybrid features,” Protein Engineering, Design & Selection, vol. 25, no. 3, pp. 119–126, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. A. A. Moya-García and J. A. G. Ranea, “Insights into polypharmacology from drug-domain associations,” Bioinformatics, vol. 29, no. 16, pp. 1934–1937, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. Z. P. Li, R. S. Wang, and X. S. Zhang, “Drug target identification based on flux balance analysis of metabolic networks,” Computational Systems Biology, vol. 13, pp. 331–338, 2010. View at Google Scholar
  35. Z. Li, R.-S. Wang, and X.-S. Zhang, “Two-stage flux balance analysis of metabolic networks for drug target identification,” BMC Systems Biology, vol. 5, no. 1, article S11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. O. Folger, L. Jerby, C. Frezza, E. Gottlieb, E. Ruppin, and T. Shlomi, “Predicting selective drug targets in cancer through metabolic networks,” Molecular Systems Biology, vol. 7, article 501, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Yang, H. Bai, Q. Ouyang, L. Lai, and C. Tang, “Finding multiple target optimal intervention in disease-related molecular network,” Molecular Systems Biology, vol. 4, p. 228, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Li, X. Zhou, W.-K. Ching, and P. Wang, “Predicting enzyme targets for cancer drugs by profiling human metabolic reactions in NCI-60 cell lines,” BMC Bioinformatics, vol. 11, article 501, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Yizhak, O. Gabay, H. Cohen, and E. Ruppin, “Model-based identification of drug targets that revert disrupted metabolism and its application to ageing,” Nature Communications, vol. 4, article 2632, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. F. Cheng, W. Li, Z. Wu et al., “Prediction of polypharmacological profiles of drugs by the integration of chemical, side effect, and therapeutic space,” Journal of Chemical Information and Modeling, vol. 53, no. 4, pp. 753–762, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. K.-J. Xu, J. Song, and X.-M. Zhao, “The drug cocktail network,” BMC Systems Biology, vol. 6, supplement 1, article S5, 2012. View at Publisher · View at Google Scholar
  42. G. V. Paolini, R. H. B. Shapland, W. P. Van Hoorn, J. S. Mason, and A. L. Hopkins, “Global mapping of pharmacological space,” Nature Biotechnology, vol. 24, no. 7, pp. 805–815, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Whitebread, J. Hamon, D. Bojanic, and L. Urban, “Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development,” Drug Discovery Today, vol. 10, no. 21, pp. 1421–1433, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Campillos, M. Kuhn, A.-C. Gavin, L. J. Jensen, and P. Bork, “Drug target identification using side-effect similarity,” Science, vol. 321, no. 5886, pp. 263–266, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. O. Bodenreider, “The Unified Medical Language System (UMLS): integrating biomedical terminology,” Nucleic Acids Research, vol. 32, pp. D267–D270, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Kuhn, M. Campillos, I. Letunic, L. J. Jensen, and P. Bork, “A side effect resource to capture phenotypic effects of drugs,” Molecular Systems Biology, vol. 6, p. 343, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Takarabe, M. Kotera, Y. Nishimura, S. Goto, and Y. Yamanishi, “Drug target prediction using adverse event report systems: a pharmacogenomic approach,” Bioinformatics, vol. 28, no. 18, Article ID bts413, pp. i611–i618, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Brouwers, M. Iskar, G. Zeller, V. van Noort, and P. Bork, “Network neighbors of drug targets contribute to drug side-effect similarity,” PLoS ONE, vol. 6, no. 7, Article ID e22187, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Carrella, F. Napolitano, R. Rispoli et al., “Mantra 2.0: an online collaborative resource for drug mode of action and repurposing by network analysis,” Bioinformatics, vol. 30, no. 12, pp. 1787–1788, 2014. View at Google Scholar
  50. T. Xu, R. Zhu, Q. Liu, and Z. Cao, “Quantitatively integrating molecular structure and bioactivity profile evidence into drug-target relationship analysis,” BMC Bioinformatics, vol. 13, no. 1, article 75, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Gönen, “Predicting drug-target interactions from chemical and genomic kernels using Bayesian matrix factorization,” Bioinformatics, vol. 28, no. 18, Article ID bts360, pp. 2304–2310, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. Y.-Y. Wang, J. C. Nacher, and X.-M. Zhao, “Predicting drug targets based on protein domains,” Molecular BioSystems, vol. 8, no. 5, pp. 1528–1534, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. K. Yang, H. Bai, Q. Ouyang, L. Lai, and C. Tang, “Finding multiple target optimal intervention in disease-related molecular network,” Molecular Systems Biology, vol. 4, article 228, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Mizutani, E. Pauwels, V. Stoven, S. Goto, and Y. Yamanishi, “Relating drug-protein interaction network with drug side effects,” Bioinformatics, vol. 28, no. 18, Article ID bts383, pp. i522–i528, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. H. Iwata, S. Mizutani, Y. Tabei, M. Kotera, S. Goto, and Y. Yamanishi, “Inferring protein domains associated with drug side effects based on drug-target interaction network,” BMC Systems Biology, vol. 7, supplement 6, p. S18, 2013. View at Publisher · View at Google Scholar
  56. D. Maglott, J. Ostell, K. D. Pruitt, and T. Tatusova, “Entrez gene: gene-centered information at NCBI,” Nucleic Acids Research, vol. 39, pp. D52–D57, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. E. Gregori-Puigjané, V. Setola, J. Hert et al., “Identifying mechanism-of-action targets for drugs and probes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 28, pp. 11178–11183, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Ashburner, C. A. Ball, J. A. Blake et al., “Gene ontology: tool for the unification of biology,” Nature Genetics, vol. 25, no. 1, pp. 25–29, 2000. View at Publisher · View at Google Scholar · View at Scopus